Full Press Release Details
eylea hd aflibercept injection 8 mg sbla accepted for fda priority review for both the treatment of macular edema following retinal vein occlusion rvo and for monthly dosing in app.
REGN
eylea hd aflibercept injection 8 mg sbla accepted for fda priority review for both the treatment of macular edema following retinal vein occlusion rvo and for monthly dosing in app
Key Takeaway: eylea hd aflibercept injection 8 mg sbla accepted for fda priority review for both the treatment of macular edema following retinal vein occlusion rvo and for monthly dosing in app